
Insulet (PODD) Stock Forecast & Price Target
Insulet (PODD) Analyst Ratings
Bulls say
Insulet is a medical device company focused on making diabetes management easier through the innovative Omnipod system. While they reported strong results in their recent quarter, the company's outlook is mixed due to lower revenue growth in the highly competitive US Type 2 market. Management is taking steps to address this issue and has plans to launch a new product in 2028, but until then, the stock may be range-bound. There are also potential risks of cybersecurity and data privacy concerns, but overall, the company's profitable international market and track record of outperformance are positive factors.
Bears say
Insulet is a leading manufacturer of the Omnipod insulin management system, with over 600,000 users worldwide. However, challenges in maintaining strong patent and trademark protections, as well as patent litigation and competition from established companies and new market entrants, could hinder the company's growth. Additionally, Insulet faces risks from market inflation and the potential for downturns in the diabetes market. While the company has a strong product offering and plans for continued growth, it may struggle in the near term due to issues with customer retention and new competition in the tubeless automated insulin delivery market.
This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.
Insulet (PODD) Analyst Forecast & Price Prediction
Start investing in Insulet (PODD)
Order type
Buy in
Order amount
Est. shares
0 shares